ethyl 2-[(tert-butoxycarbonyl)amino]-4-trifluoromethyl-1,3-thiazole-5-carboxylate | 302963-96-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2-[(tert-butoxycarbonyl)amino]-4-trifluoromethyl-1,3-thiazole-5-carboxylate
• 英文别名: 2-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)thiazole-5-carboxylic acid ethyl ester；ethyl 2-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)thiazole-5-carboxylate；(5-ethoxycarbonyl-4-trifluoromethylthiazol-2-yl)carbamic acid, 1,1-dimethylethyl ester；ethyl-2-tert-butoxycarbonyloxyamino-4-trifluoromethyl-thiazole-5-carboxylate；2-tert-Butoxycarbonylamino-4-trifluoromethyl-thiazole-5-carboxylic acid ethyl ester；ethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate
• CAS: 302963-96-8
• 化学式: C₁₂H₁₅F₃N₂O₄S
• 分子量: 340.323
• InChiKey: ALNFWXQKGZXCPT-UHFFFAOYSA-N

物化性质

• 密度：
  1.366±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  ethyl 2-[(tert-butoxycarbonyl)amino]-4-trifluoromethyl-1,3-thiazole-5-carboxylate 在 盐酸 、 水 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.75h， 生成 (S)-2-[(2-tert-Butoxycarbonylamino-4-trifluoromethyl-thiazole-5-carbonyl)-amino]-3-[(thiophene-2-carbonyl)-amino]-propionic acid methyl ester
  参考文献：
  名称：

  THIAZOLE AND THIOPHENE COMPOUNDS

  摘要：

  本文提供的是式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗炎症性疾病和紊乱，例如哮喘和慢性阻塞性肺病，是有用的。

  公开号：

  US20120238569A1
• 作为产物：
  描述：

  三氟乙酰乙酸乙酯 在 4-二甲氨基吡啶 、 碘 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 4.0h， 生成 ethyl 2-[(tert-butoxycarbonyl)amino]-4-trifluoromethyl-1,3-thiazole-5-carboxylate
  参考文献：
  名称：

  Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides

  摘要：

  A random high-throughput screening (HTS) program to discover novel normucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out with MT-4 cells against a nevirapine-resistant virus, HIV-1(IIIB-R). The primary hit, a thiazolidene-benzenesulfonamide derivative, possessed good activity. A systematic modification program examining various substituents at the 3-, 4-, and 5-positions on the thiazole ring afforded compounds with enhanced anti-HIV-1 and reverse transcriptase (RT) inhibitory activities. These results confirm the important role of the substituents at these positions and the thiazolidenebenzenesulfonamide motif as a valuable lead series for the next generation NNRTIs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.08.050

文献信息

• Dehydroamino acids
  申请人：——

  公开号：US20020161237A1

  公开（公告）日：2002-10-31

  Compounds of formula 1 and 1-1, 1 wherein R 1 is hydrogen, hydroxy, amino or halogen, R 2 is hydrogen, hydroxy, or halogen and R 3 is hydrogen (Formula 1) or R 1 is hydrogen and R 2 and R 3 taken together with the ethenylene group connecting them form phenyl, pyrrole, pyrroline, oxopyrroline, pyrazole, triazole, or imidazole (Formula 1-1), A is 2 R 4 R 5 are hydrogen, methyl, ethyl or halogen except that R 4 r 5 cannot both be hydrogen; and 1) B is hydrogen, or lower alkyl; or 2) B is 3 where R 6 R 7 R 8 and R 9 are independently hydrogen, hydroxy, aminosulfonyl, halogen, lower alkoxy, cyano, amino, lower alkyl, lower alkyl amino, or nitro; or 3) B is 4 where R 10 is hydrogen, hydroxy, halogen, or lower alkyl and C is a five- or six- membered ring with 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur, which ring may be unsubstituted or mono- or di- substituted with lower alkyl, cycloalkyl, amino, or substituted amino; 4) B is 5 where X and Y are independently methylene or nitrogen; or 5) B is 6 where at leat one of T, U, V, or W is nitrogen, and any of T, U, V or W which is carbon may be substituted with lower alkyl, lower alkyl amino, lower alkoxy, hydroxy, aminosulfonyl, halogen, cyano, amino, or nitro; or 6) B is 7 where Y is carbon or nitrogen; or 7) B is a five-membered aromatic ring with 1 to 3 heteratoms selected from nitrogen, oxygen, and sulfur which ring may be unsubstituted or mono- or di-substituted with lower alkyl, cycloalky, trifluoroloweralkyl, amino, halogen, substituted amino, or which ring may be fused with a 5 or 6 membered aromatic ring containing 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur; and pharmaceutically acceptable salts thereof, and related prodrugs, pharmaceutical compositions and methods of treatment, which compounds are useful for treating psoriasis.

  式1和1-1的化合物， 其中R1是氢，羟基，氨基或卤素，R2是氢，羟基或卤素，R3是氢（式1）或R1是氢，R2和R3连同连接它们的乙烯基团形成苯基，吡咯，吡咯烯，氧代吡咯烯，吡唑，三唑或咪唑（式1-1），A是 R4R5是氢，甲基，乙基或卤素，但R4R5不能同时为氢；和 1）B是氢或低碳烷基；或 2）B是 R6R7R8和R9独立地是氢，羟基，氨基磺酰基，卤素，低烷氧基，氰基，氨基，低烷基，低烷基氨基或硝基； 或3）B是 R10是氢，羟基，卤素或低碳烷基，C是具有0到3个异原子的五元或六元环，这些异原子选自氮，氧和硫，该环可以未取代或单取代或双取代为低烷基，环烷基，氨基或取代氨基； 4）B是 X和Y独立地是亚甲基或氮；或 5）B是 至少T，U，V或W中的一个是氮，任何是碳的T，U，V或W可以被低烷基，低烷基氨基，低烷氧基，羟基，氨基磺酰基，卤素，氰基，氨基或硝基取代；或 6）B是 Y是碳或氮； 或 7）B是具有1到3个异原子的氮，氧和硫中选择的五元芳香环，该环可以未取代或单取代或双取代为低烷基，环烷基，三氟低烷基，氨基，卤素，取代氨基，或该环可以与含有0到3个异原子的五元或六元芳香环融合，这些异原子选自氮，氧和硫；及其药学上可接受的盐，相关的前药，药物组合物和治疗方法，这些化合物对治疗牛皮癣有用。
• Cyclic protein tyrosine kinase inhibitors
  申请人：——

  公开号：US20040054186A1

  公开（公告）日：2004-03-18

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  新型环状化合物及其盐类，含有此类化合物的药物组合物，以及使用此类化合物治疗蛋白质酪氨酸激酶相关疾病，如免疫和肿瘤疾病的方法。
• Thiazole and thiophene compounds
  申请人：Gillespie Paul

  公开号：US08404859B2

  公开（公告）日：2013-03-26

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

  本文提供的是公式（I）的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及其含有它们的药物组合物，可用于治疗炎症性疾病和疾病，例如哮喘和慢性阻塞性肺疾病。
• NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20160244444A1

  公开（公告）日：2016-08-25

  To provide a compound having an inhibitory activity for an androgen receptor. A tetrahydropyridopyrimidine compound represented by the following general formula (I) or a pharmaceutically acceptable thereof (in the formula, X and R are as defined in the specification).

  提供一种具有抑制雄激素受体活性的化合物。该化合物为以下通式（I）所代表的四氢吡啶嘧啶化合物或其药学上可接受的衍生物（其中，X和R如规范中所定义）。
• Tetrahydropyridopyrimidine compound or salt thereof
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US10300067B2

  公开（公告）日：2019-05-28

  A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

  一种抑制雄激素活性的方法，包括向有需要的受试者施用有效量的式(I)四氢吡啶嘧啶化合物或其药学上可接受的盐，以及一种治疗肿瘤的方法，包括向有需要的受试者施用有效量的式(I)四氢吡啶嘧啶化合物或其药学上可接受的盐